Current perspective on rituximab in rheumatic diseases.

Area of Science:

• Rheumatology
• Immunology
• Pharmacology

Background:

• Biologics have transformed autoimmune rheumatic disease treatment, improving patient quality of life.
• Rituximab (RTX), a monoclonal antibody targeting CD20+ B cells, is approved for rheumatoid arthritis and vasculitis.
• RTX is also used off-label for systemic sclerosis, Sjögren's syndrome, and systemic lupus erythematosus.

Purpose of the Study:

• To review the role of rituximab (RTX) in autoimmune rheumatic diseases.
• To discuss the mechanism of action of RTX in reducing inflammation and tissue damage.
• To highlight the significance of RTX biosimilars in improving treatment accessibility and cost-effectiveness.

Main Methods:

• Review of existing literature on rituximab's use in rheumatology.
• Analysis of RTX's mechanism of action, including B cell depletion and apoptosis induction.
• Discussion of RTX's efficacy in approved and off-label indications.

Main Results:

• Rituximab (RTX) effectively depletes B cells, reducing immune complex deposition and subsequent inflammation.
• RTX demonstrates significant clinical benefits in rheumatoid arthritis and anti-neutrophil cytoplasmic antibodies-associated vasculitis.
• Off-label use of RTX shows promise in managing systemic sclerosis, Sjögren's syndrome, and systemic lupus erythematosus.

Conclusions:

• Rituximab (RTX) is a valuable therapeutic option for autoimmune rheumatic diseases due to its B cell-depleting mechanism.
• The availability of RTX biosimilars, like CT-P10, is crucial for expanding patient access and reducing healthcare costs.
• Further research into RTX and its biosimilars will continue to optimize treatment strategies for chronic inflammatory rheumatic conditions.